Domov › Akútna biphenotypová leukémia › Ohio
Klinické štúdie Akútna biphenotypová leukémia v štáte Ohio
8 štúdií pre Akútna biphenotypová leukémia hľadá účastníkov v zariadeniach v štáte Ohio.
Mestá v štáte Ohio
Oficiálny text štúdie (anglicky)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- a 2 ďalších
Prebieha náborFáza 2
365 Days · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Ohio State University, Columbus
Prebieha náborFáza 1/2
30 Days · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- a 4 ďalších
Prebieha náborFáza 3
365 Days – 25 Years · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- a 3 ďalších
Prebieha náborFáza 1/2
Do veku 22 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04726241Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
Prebieha náborFáza 1/2
Vek 13 až 90 · Všetky pohlavia · Aktualizované 6. 8. 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Cincinnati Children's Hospital Medical Center, Cincinnati
Prebieha náborFáza 1
Vek 1 až 30 · Všetky pohlavia · Aktualizované 3. 8. 2026 · NCT06177067The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
Prebieha náborFáza 1/2
Vek 12 až 95 · Všetky pohlavia · Aktualizované 15. 4. 2026 · NCT04329728Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies, Cleveland
- Nationwide Children's Hospital, Columbus
Prebieha náborFáza 1
Vek 1 až 21 · Všetky pohlavia · Aktualizované 6. 12. 2024 · NCT05476770Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.